Literature DB >> 16968412

Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Y Luo1, H Yamada, D P Evanoff, X Chen.   

Abstract

Previously, we have demonstrated that macrophages exhibited cytotoxicity toward mouse bladder cancer MBT-2 cells upon bacille Calmette-Guérin (BCG) stimulation. In this study, we have investigated the role of Th1-stimulating cytokines in BCG-induced macrophage cytotoxicity. Thioglycollate-elicited peritoneal exudate cells (PECs) were used as a conventional source for macrophages and the induction of PEC effector functions (cytolytic activity and cytokine production) by BCG was evaluated in vitro. The BCG-activated PECs showed potent cytotoxicity and killed MBT-2 cells in a dose-dependent manner. Depletion of T cells, natural killer (NK) cells, or both, in PEC preparations exhibited a marginal or small reduction of MBT-2 cell killing, suggesting that macrophages played a primary role in PEC cytotoxicity. Transwell assays indicated that the maximal PEC cytotoxicity required both direct cell-cell contact and soluble factors such as interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha. Neutralizing endogenous cytokines interleukin (IL)-12, IL-18, IFN-gamma or TNF-alpha reduced PEC cytotoxicity by 38%, 22%, 15% and 94%, respectively. Supplementation of BCG with recombinant (r)IL-2, rIL-12 or rIL-18 increased PEC cytotoxicity by approximately twofold. Compared with control BCG for PEC stimulation, rBCGs expressing IL-2 or IL-18 showed enhanced MBT-2 cell killing by PECs. Increased cytokine production (IFN-gamma, TNF-alpha and IL-6) was also observed in rBCG-stimulated PEC cultures. Taken together, these results suggest that Th1-stimulating cytokines play an important role in BCG-induced macrophage cytotoxicity and that combination of BCG with selected Th1-stimulating cytokines, either supplemented or expressed by BCG, may enhance the effect of BCG in the treatment of bladder cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968412      PMCID: PMC1809722          DOI: 10.1111/j.1365-2249.2006.03191.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.

Authors:  H J Ahn; S Maruo; M Tomura; J Mu; T Hamaoka; K Nakanishi; S Clark; M Kurimoto; H Okamura; H Fujiwara
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?

Authors:  T M de Reijke; E C De Boer; K H Kurth; D H Schamhart
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

3.  Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells.

Authors:  H Matsumoto; K Suzuki; K Tsuyuguchi; E Tanaka; R Amitani; A Maeda; K Yamamoto; M Sasada; F Kuze
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

4.  Lethal tuberculosis in interleukin-6-deficient mutant mice.

Authors:  C H Ladel; C Blum; A Dreher; K Reifenberg; M Kopf; S H Kaufmann
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

5.  IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.

Authors:  K Kohno; J Kataoka; T Ohtsuki; Y Suemoto; I Okamoto; M Usui; M Ikeda; M Kurimoto
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

6.  Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin.

Authors:  M Emoto; Y Emoto; I B Buchwalow; S H Kaufmann
Journal:  Eur J Immunol       Date:  1999-02       Impact factor: 5.532

7.  Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.

Authors:  M A O'Donnell; A Aldovini; R B Duda; H Yang; A Szilvasi; R A Young; W C DeWolf
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  Exogenous interferon-gamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase.

Authors:  A Zhou; Z Chen; J A Rummage; H Jiang; M Kolosov; I Kolosova; C A Stewart; R W Leu
Journal:  J Interferon Cytokine Res       Date:  1995-10       Impact factor: 2.607

9.  Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.

Authors:  T M de Reijke; E C de Boer; K H Kurth; D H Schamhart
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

10.  Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.

Authors:  K Pryor; J Goddard; D Goldstein; P Stricker; P Russell; D Golovsky; R Penny
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more
  24 in total

1.  Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cells.

Authors:  Phillip H Horne; Jason M Zimmerer; Mason G Fisher; Keri E Lunsford; Gyongyi Nadasdy; Tibor Nadasdy; Nico van Rooijen; Ginny L Bumgardner
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

2.  A novel accessory molecule Trim59 involved in cytotoxicity of BCG-activated macrophages.

Authors:  Xiangfeng Zhao; Qihui Liu; Baiqiu Du; Peng Li; Qu Cui; Xiao Han; Bairong Du; Dongmei Yan; Xun Zhu
Journal:  Mol Cells       Date:  2012-09-03       Impact factor: 5.034

Review 3.  Immune checkpoint inhibitors: a new frontier in bladder cancer.

Authors:  Max Kates; Nikolai A Sopko; Hotaka Matsui; Charles G Drake; Noah M Hahn; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2015-10-20       Impact factor: 4.226

4.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

5.  Inhibition of mycobacterial infection by the tumor suppressor PTEN.

Authors:  Guochang Huang; Gil Redelman-Sidi; Neal Rosen; Michael S Glickman; Xuejun Jiang
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

6.  Immunomodulatory effects of recombinant BCG expressing MSP-1C of Plasmodium falciparum on LPS- or LPS+IFN-γ-stimulated J774A.1 cells.

Authors:  Dhaniah Mohamad; Rapeah Suppian; Norazmi Mohd Nor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Authors:  Robert S Svatek; Xiang Ru Zhao; Edwin E Morales; Mithilesh K Jha; Timothy Y Tseng; Cory M Hugen; Vincent Hurez; Javier Hernandez; Tyler J Curiel
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

8.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

Review 9.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

Review 10.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.